pharmaphorum4d
Hutchmed cashes in a Chinese JV to help fund its pipeline
The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...
Yahoo Finance4d
HUTCHMED to divest 45% equity interest in SHPL for $608m
HUTCHMED (China) has agreed to sell a 45% equity interest in the non-core, non-consolidated joint venture (JV) Shanghai ...
FiercePharma4d
With $608M divestment, Hutchmed continues to focus on ADC development
In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...
Hutchmed announces progress, hits milestone with lung cancer treatment
Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment ...
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week
HUTCHMED (China) is not owned by hedge funds. Hutchison Whampoa (China) Limited is currently the largest shareholder, with 39% of shares outstanding. In comparison, the second and third largest ...
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including ...
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative ...
The Pharma Letter4d
Hutchmed divests joint venture for $608 million
Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...
GlobalData on MSN3d
China’s NMPA prioritises HUTCHMED’s lung cancer therapy review
China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...